ASX300 rebalancing should of already been done.
If they can't resolve the "packing" issue with Aridol then it's another excuse to sell down. Also, I've considered the risk that Novaquest could cause a "black swan" event and decide they're not willing to front up with the additional 20 million, which is suppose to become available next year for another CF trial. 12 cents wouldn't be looking so cheap then.
Buying at these levels does look attractive though, but buyer beware.
cash 2x market cap, page-19
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
